Randomized placebo controlled trial· 2017

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial

Campbell C, McMillan HJ, Mah JK, et al.

Muscle and Nerve

PubMed
27462804
Evidence level
moderate
Verification
verified

Summary

Ascending-dose randomized trial of ACE-031 in ambulatory boys with Duchenne muscular dystrophy, primarily evaluating safety.

Limitations

Premature termination, small sample, short duration and exploratory functional outcomes.

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.